ClinicalTrials.gg
TerminatedNCT02968160Updated Apr 12, 2019

A Clinical Trial of YMC017 in Hypertensive and Hypercholesterolemic Patients With Metabolic Syndrome

A Phase 4 interventional study of Telmisartan 40mg + Rosuvastatin 20mg and Telmisartan 80mg + Rosuvastatin 20mg in Metabolic Syndrome, sponsored by Yuhan Corporation. Terminated at 1 site in Korea, Republic of. Open to participants aged 19 Years to 79 Years. Per ClinicalTrials.gov, last updated 2019-04-12.

Sponsored by Yuhan Corporation · Phase 4, Interventional, and Treatment

Why this study was terminated
Due to poor enrollment rate

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
55
Allocation
Randomized
Ages
19 Years to 79 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 53 studies in Metabolic Syndrome with a site in Korea, Republic of — 4 open to participants now, 4 under way, none of them phase 3. Metabolic Syndrome · Korea, Republic of.

Enrollment
23rd of 31
55 · median 67
Started
2016
with 1 other
Phase 4
11 of 53
1 open now
Registered
41st of 53
by date

Among the 53 studies in Metabolic Syndrome with a site in Korea, Republic of, this one is the 23rd largest by enrollment of the 31 interventional ones that give a count, is one of 2 that started in 2016, is one of 11 in phase 4, and was the 41st registered.

Metabolic Syndrome

2,117 studies on the registry are indexed under Metabolic Syndrome; 347 are open to participants now.

Browse Metabolic Syndrome studies →

Open to participants now

4 of the 53 studies in Metabolic Syndrome with a site in Korea, Republic of are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 232 Metabolic Syndrome studies recruiting now, 68 (29%) set no upper age limit and 135 (58%) stop at 75 or younger; 20 take children under 18; 80 take healthy volunteers.

This study: 19 Years to 79 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 53 studies in Metabolic Syndrome with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This is a Randomized, open-label, 2 groups, parallel design.

Read the detailed description

This study objective is to compare the safety and efficacy between fixed dose combination (Duowell® tab) and free pill combination therapy of Telmisartan and Rosuvastatin in hypertensive and hypercholesterolemic patients with metabolic syndrome.

03

Conditions studied

  • Metabolic Syndrome

Browse trials for

04

Who can participate

Ages eligible
19 Years to 79 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 19 and 79 years old at screening visit
  • Subjects who have being used anti-hypertension drugs and Lipid lowering agents over 4weeks before randomization.
  • Subjects who have been diagnosed with metabolic syndrome according to following criteria Definition of patients with metabolic syndrome: Patients satisfy two of the following criteria at least

    • Abdominal obesity: Waist measurement > 90 cm(male), > 80 cm(female)
    • Triglyceride(TG) ≥ 150 mg/dL(
    • High-Density Lipoprotein Cholesterol(HDL-C) \< 40 mg/dL(male), \< 50 mg/dL (female)
    • Fasting Plasma Glucose(FPG) ≥ 100 mg/dL or Subject who has being used oral hypoglycemic agents
  • women have certainly negative of the pregnancy test at screening visit (visit 1), and agree to implement the effective during the study period(including the medically non-pregnant state)
  • Subjects who have signed after fully understanding the purpose, content, characteristics and risk of the product and get explained enough.

Exclusion criteria

Exclusion Criteria:

  • Subjects who taking anti-hypertension drugs more than three agent
  • Subjects who have mean Sitting Systolic Blood Pressure(siSBP) > 160 mmHg (excluded if appliable, one of the arms)
  • Subjects who have blood pressure ≥ 140/90 mmHg with taking 2 or more anti-hypertension drugs (except if any of the arms)
  • Subjects that Low Density Lipoprotein-Cholesterol(LDL-C) isn't properly controlled according to National Cholesterol Education Program Adults Treatment Panel (NCEP ATP) III criteria
  • Subjects who have triglyceride (TG) ≥ 400mg/dL
  • Subjects who have a difference more than 20mmHg at the mean Sitting Diastolic Blood Pressure(siSBP) measured three times in both arms.
  • Other exclusions applied
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Telmisartan+Rosuvastatin

    Duowell ® tablet (Telmisartan 40mg + Rosuvastatin 20mg) 1 tablet, once daily, Oral administration/ 8 weeks \* But, the increased Duowell ® tablet (Telmisartan 80mg + Rosuvastatin 20mg) will get administrated orally one tablet once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit.

    Drug: Telmisartan 40mg + Rosuvastatin 20mg · Drug: Telmisartan 80mg + Rosuvastatin 20mg

  • Active comparator
    Telmisartan/Rosuvastatin

    Telmisartan 40mg + Rosuvastatin 20mg 2 tablets, once daily, Oral administration/ 8 weeks \* But, the increased Telmisartan 80mg + Rosuvastatin 20mg will get administrated orally 2 tablets once daily to the subjects who have mean systolic blood pressure more than 140mmHg based on arm, which was determined before, at 4week visit.

    Drug: Telmisartan 40mg, 80 mg · Drug: Rosuvastatin 20mg

Interventions

06

What researchers measure

Primary outcomes

  1. The proportion of subjects that the mean Sitting Diastolic Blood Pressure(siSBP) and Low Density Lipoprotein-Cholesterol(LDL-C) level reach the treatment goals after 8 weeks from investigational product administration.

    Time frame: week 8

Secondary outcomes

  1. Change of Low Density Lipoprotein-Cholesterol(LDL-C) from baseline to 4 and 8 weeks

    Time frame: From baseline to 4 and 8 weeks

  2. Change of Sitting Systolic Blood Pressure(siSBP) and Sitting Diastolic Blood Pressure(siDBP) from baseline to 4 and 8 weeks

    Time frame: From baseline to 4 and 8 weeks

  3. The proportion of subjects that the mean sitting blood pressure(siBP) level reaches the treatment goals to 4 and 8 weeks

    Time frame: 4 and 8 weeks

  4. The proportion of subjects that the Low Density Lipoprotein-Cholesterol(LDL-C) level reaches treatment goals in accordance with guideline of National Cholesterol Education Program-Adult Treatment Panel(NCEP ATP) III to 4 and 8 weeks

    Time frame: 4 and 8 weeks

  5. Change of below indicators from baseline to 4 and 8 weeks

    Time frame: baseline to 4 and 8 weeks

07

Study locations

1 site
  • Dongguk University Medical Center
    Ilsan, 10326, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2016, a primary completion of Feb 2018 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2016
First posted
Nov 18, 2016
Start
Oct 2016
Primary completionActual
Feb 2018
CompletionActual
Feb 2018
Last update
Apr 12, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02968160
Lead sponsor
Yuhan Corporation
Collaborators
Linical Korea
Responsible party
Sponsor
First posted
Nov 18, 2016
Start date
Oct 2016
Primary completion
Feb 2018
Completion
Feb 2018
Last update
Apr 12, 2019

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Telmisartan

Start the discussion